Twelve days after a clinical paper from this station’s medical service described the first human disease caused by templating across the chirality barrier, Boreas Station has no test to offer its residents, no register to check, and no treatment to promise. The paper, published on 4 December in the Journal of Clinical Neuropathology, reports an index case at this station and estimates that between 3,400 and 11,200 people across the settled sphere are carrying the condition, most without knowing it (Haddad et al., 2179).
The finding is that a free-licensed medicine, in use across the settled sphere since 2130, carried trace D-chiral template fragments that in a minority of recipients templated an endogenous protein into a mirror-image fold. The fold is invisible to every diagnostic reagent and clearance therapy in the standard kit, because those reagents were built for the opposite handedness. The station’s medical service is one of the two laboratories in the system that can currently detect it.
”There Is No Test to Offer”
Dr. Noor Haddad, of the station’s medical service and first author of the paper, said the clinic has been receiving requests since publication.
“We can enrol people in the follow-up study. That is not the same as telling them anything,” Haddad said. “The mirror-selective assay exists in our laboratory and in one laboratory at Dome 4. It is not a clinical test. It has not been validated for screening, and we do not yet know what a positive result means in a person with no symptoms. I have had four conversations this week that ended with me saying I don’t know.”
Haddad confirmed that the station is not recommending imaging for asymptomatic recipients. “A positive scan tells you there is a beta-sheet aggregate. It does not tell you which one. We found this disease because a patient had symptoms. We cannot find it in people who do not.”
The paper does not name the index patient and identifies her only by age, sex, and occupation.
”I Took It for Six Years”
Yusra Demir, 64, has worked the Titan surface greenhouse basins for thirty-one years, the same occupational pool the paper describes for the index patient. She received a course of the 2130 class between 2146 and 2152 for a chronic inflammatory condition.
“I did the arithmetic before they finished the segment,” Demir said. “Three thousand four hundred to eleven thousand, out of three hundred thousand. That is one in ninety at the low end and one in twenty-eight at the high end. Nobody will tell me which. There is a number that describes whether I am in it, and the number exists somewhere, and it is not available to me.”
Demir said she has not requested testing. “There is no test. Asking again does not make one."
"We Watched the Wrong Door”
Rune Aalto has worked the Saturnian containment programme for twenty-two years, most of it on the six D-chiral moons the programme was established to keep separate.
“The assumption was contact. You contain a moon, you contain a biosphere, you keep the two biologies apart,” Aalto said. “Nobody in this programme was ever asked to read a formulary. The material left the moons in a licensed product, went into people’s arms on stations we do not inspect, and did that for forty-nine years while we were doing our jobs correctly.”
Aalto said morale on the programme is not the problem. “The finding says containment as we have practised it is not a boundary. It is a perimeter around one kind of route. There are others, and we were never given authority over any of them.”
The Register That Was Never Kept
The 2130 patent was released under free license rather than held, following the open-license precedent of Neuromorphic Foundries’ 2062 release (UN Weekly, 2130). No licensor remained to keep a recipient register, and no system-wide one was established. The paper’s recipient figure of approximately 310,000 was reconstructed from manufacturing lot records, dispensary logs at fourteen facilities, and two settlement health authorities that happened to keep their own.
Dome 4 referred questions to the paper and declined further comment. Nova Biosciences, whose clearance regimens are licensed at seven stations and which has been in litigation with Dome 4 since 2155 over a separate chiral delivery architecture, declined to comment, citing pending proceedings before the Luna Interplanetary Court.
The Titan surface health authority has suspended new prescriptions of the 2130 class pending a lot review, a step the paper’s authors neither recommended nor opposed. No recall of existing stock has been ordered. Asked what a patient currently on the class should do, the authority said only that patients should consult their prescriber.
What the Station Is Asking For
The paper’s four recommendations, none of which is in place, are a retrospective exposure register to 2130, reanalysis of every archived case of undetermined proteinopathy, screening of living recipients, and extension of the containment protocol to manufacturing chains. The UN Office for Colonial Development said in a one-paragraph statement that it is “reviewing the findings and their implications for settlement health policy” and has no timeline for a response.
Haddad, asked what the station should do while it waits, gave an answer that was not clinical. “The paper estimates thousands of people. Some of them are on this station. The containment programme is funded and the clinic is funded. Whatever the clearance agent becomes, it will not be funded. It will be licensed. That is the part of this I am least able to help with.”
What Is Still Open
The paper states plainly that causation is not established, that no in vivo data exist for the candidate agent, and that the attack rate is derived from a screened sample of 1,240 people and a series of 58. The authors describe an association that is temporal, structural, and consistent in every case where exposure could be documented. They do not describe a cure.
There is no test at this station. There is no register to check. There is no timeline from any authority that has been asked.
This outlet will continue coverage. Residents seeking enrolment in the follow-up study should contact the station medical service. The service has asked this outlet to state that it cannot provide individual risk assessments at this time.